MV-130 is under clinical development by Inmunotek and currently in Phase II for Respiratory Tract Infections. According to GlobalData, Phase II drugs for Respiratory Tract Infections have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MV-130’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MV-130 overview
MV-130 (Bactek) is under development for the treatment of chronic obstructive pulmonary disease (COPD) and pneumonia due to COVID-19 infection. MV-130 is a bacterial polyvalent vaccine composed of different proportions of whole heat-inactivated gram-positive and gram-negative bacteria often present in the nasal mucosa and frequently involved in upper and lower respiratory infections (60 percent Streptococcus pneumoniae, 15 percent Staphylococcus aureus, 15 percent Staphylococcus epidermidis, 4 percent Klebsiella pneumoniae, 3 percent Moraxella catarrhalis, 3 percentHaemophilus influenzae), urinary tract infections. It is administered as sublingual spray or suspension intranasal formulation. It was also under development for treatment of bronchospasm induced by recurrent respiratory tract infections
Inmunotek overview
Inmunotek opearates as a pharmaceutical company. It develops, produces and markets products for allergy and other immune-based diseases and manufactures veterinary medicine. It also produces raw materials such as biological products, including fungi, bacteria and mites.
For a complete picture of MV-130’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
